For the quarter ending 2026-03-31, IONS made $246,091K in revenue. -$92,528K in net income. Net profit margin of -37.60%.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 246,091 | 156,719 | 452,049 | - |
| Cost of sales | 2,983 | 2,338 | 4,151 | - |
| Research, development and patent | 210,173 | 217,754 | 217,460 | - |
| Selling, general and administrative | 150,359 | 96,809 | 90,622 | - |
| Total operating expenses | 363,515 | 316,901 | 312,233 | - |
| Loss from operations | -117,424 | -160,182 | 139,816 | -146,860 |
| Investment income | 25,484 | 23,682 | 24,687 | 24,667 |
| Interest expense | 5,160 | 4,212 | 4,114 | 4,108 |
| Interest expense related to sale of future royalties | 17,337 | 17,952 | 18,648 | 18,822 |
| Gain (loss) on investments, net | 22,583 | 29,908 | -18,312 | -2,164 |
| Other income (expense), net | -456 | 363 | 102 | 465 |
| Loss before income tax expense | -92,310 | -128,393 | 123,531 | -146,822 |
| Income tax expense | 218 | 213 | -20 | 116 |
| Net loss | -92,528 | -128,606 | 123,551 | -146,938 |
| Basic EPS | -0.56 | -0.8 | 0.78 | -0.93 |
| Diluted EPS | -0.56 | -0.8 | 0.7 | -0.93 |
| Basic Average Shares | 164,874,000 | 159,765,000 | 159,137,000 | 158,735,000 |
| Diluted Average Shares | 164,874,000 | 159,765,000 | 182,331,000 | 158,735,000 |
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)